Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s):  CSCI

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:CSCI - Post by User

Post by prophetoffactzon Sep 12, 2024 6:08pm
52 Views
Post# 36221254

Those suffering osteoarthritis, diabetes, and heart disease

Those suffering osteoarthritis, diabetes, and heart diseaseOsteoarthritis (OA) is a prevalent chronic condition that significantly impacts various aspects of health, particularly in relation to cardiovascular diseases (CVD) and diabetes. The interplay between OA and these comorbidities can complicate wound healing and overall health management.

Osteoarthritis and Cardiovascular Disease

Research indicates that individuals with OA face an increased risk of developing cardiovascular diseases. A study utilizing data from the Canadian Community Health Survey found that OA is associated with a 45% increased odds of prevalent heart disease, with even higher risks observed for conditions such as angina and congestive heart failure. Furthermore, a meta-analysis highlighted that knee OA patients have a 24% increased risk of CVD compared to those without OA, with severe cases showing even higher risks.The mechanisms linking OA and CVD include shared risk factors such as obesity, physical inactivity, and systemic inflammation. Inactivity due to joint pain can exacerbate cardiovascular risks, leading to a vicious cycle of worsening health outcomes.

Osteoarthritis and Diabetes

The relationship between OA and diabetes is also significant. Individuals with OA are at a heightened risk of developing type 2 diabetes, with studies indicating a 50% increased likelihood compared to those without joint disease. This association is largely attributed to obesity, which is a common risk factor for both conditions. Additionally, diabetes can complicate OA management and increase the risk of joint-related complications, further impeding mobility and increasing the likelihood of cardiovascular issues.

Implications for Wound Healing

The presence of OA, along with comorbidities like diabetes and cardiovascular disease, can adversely affect wound healing. Poor circulation associated with cardiovascular issues and the metabolic complications from diabetes can lead to delayed healing and increased risk of infections. Moreover, the pain and immobility caused by OA can limit physical activity, which is crucial for maintaining overall health and promoting effective healing processes.In summary, the interplay between osteoarthritis, cardiovascular disease, and diabetes creates a complex health landscape that can hinder effective wound healing. Addressing these comorbidities through comprehensive management strategies is essential for improving patient outcomes.
<< Previous
Bullboard Posts
Next >>